Literature DB >> 18485022

Involution of infantile haemangiomas after imiquimod 5% cream.

R B M Barry1, B R Hughes, L J Cook.   

Abstract

Infantile haemangioma is a common childhood condition, which usually resolves spontaneously and is managed expectantly. In a small percentage of complex cases, haemangiomas may be associated with complications such as persistent bleeding, ulceration, feeding difficulties or visual impairment. Active treatment is often necessary in such cases. Current interventions include surgical, laser and immunomodulatory treatments. Imiquimod 5% cream is a novel alternative topical treatment that may have a potential role in management of these patients. We present our experience of imiquimod 5% cream in the treatment of five children with difficult haemangiomas. We discuss its efficacy and some of the side effects that may be encountered, which have not previously been reported.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18485022     DOI: 10.1111/j.1365-2230.2007.02676.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  8 in total

1.  Topical imiquimod treatment of cutaneous vascular disorders in pediatric patients: clinical evaluation on the efficacy and safety.

Authors:  Xiao-hong Mao; Jian-you Wang; Jian-liang Yan
Journal:  J Zhejiang Univ Sci B       Date:  2012-09       Impact factor: 3.066

Review 2.  Cutaneous lesions of the nose.

Authors:  Michael Sand; Daniel Sand; Christina Thrandorf; Volker Paech; Peter Altmeyer; Falk G Bechara
Journal:  Head Face Med       Date:  2010-06-04       Impact factor: 2.151

Review 3.  A practical guide to treatment of infantile hemangiomas of the head and neck.

Authors:  Jia Wei Zheng; Ling Zhang; Qin Zhou; Hua Ming Mai; Yan An Wang; Xin Dong Fan; Zhong Ping Qin; Xv Kai Wang; Yi Fang Zhao
Journal:  Int J Clin Exp Med       Date:  2013-10-25

4.  Japanese clinical practice guidelines for vascular anomalies 2017.

Authors:  Hidefumi Mimura; Sadanori Akita; Akihiro Fujino; Masatoshi Jinnin; Mine Ozaki; Keigo Osuga; Hiroki Nakaoka; Eiichi Morii; Akira Kuramochi; Yoko Aoki; Yasunori Arai; Noriko Aramaki; Masanori Inoue; Yuki Iwashina; Tadashi Iwanaka; Shigeru Ueno; Akihiro Umezawa; Michio Ozeki; Junko Ochi; Yoshiaki Kinoshita; Masakazu Kurita; Shien Seike; Nobuyuki Takakura; Masataka Takahashi; Takao Tachibana; Kumiko Chuman; Shuji Nagata; Mitsunaga Narushima; Yasunari Niimi; Shunsuke Nosaka; Taiki Nozaki; Kazuki Hashimoto; Ayato Hayashi; Satoshi Hirakawa; Atsuko Fujikawa; Yumiko Hori; Kentaro Matsuoka; Hideki Mori; Yuki Yamamoto; Shunsuke Yuzuriha; Naoaki Rikihisa; Shoji Watanabe; Shinichi Watanabe; Tatsuo Kuroda; Shunsuke Sugawara; Kosuke Ishikawa; Satoru Sasaki
Journal:  Jpn J Radiol       Date:  2020-04       Impact factor: 2.374

5.  Japanese Clinical Practice Guidelines for Vascular Anomalies 2017.

Authors:  Hidefumi Mimura; Sadanori Akita; Akihiro Fujino; Masatoshi Jinnin; Mine Ozaki; Keigo Osuga; Hiroki Nakaoka; Eiichi Morii; Akira Kuramochi; Yoko Aoki; Yasunori Arai; Noriko Aramaki; Masanori Inoue; Yuki Iwashina; Tadashi Iwanaka; Shigeru Ueno; Akihiro Umezawa; Michio Ozeki; Junko Ochi; Yoshiaki Kinoshita; Masakazu Kurita; Shien Seike; Nobuyuki Takakura; Masataka Takahashi; Takao Tachibana; Kumiko Chuman; Shuji Nagata; Mitsunaga Narushima; Yasunari Niimi; Shunsuke Nosaka; Taiki Nozaki; Kazuki Hashimoto; Ayato Hayashi; Satoshi Hirakawa; Atsuko Fujikawa; Yumiko Hori; Kentaro Matsuoka; Hideki Mori; Yuki Yamamoto; Shunsuke Yuzuriha; Naoaki Rikihisa; Shoji Watanabe; Shinichi Watanabe; Tatsuo Kuroda; Shunsuke Sugawara; Kosuke Ishikawa; Satoru Sasaki
Journal:  J Dermatol       Date:  2020-03-22       Impact factor: 4.005

6.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

7.  Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double-blind randomized controlled trial.

Authors:  Ali Asilian; Fatemeh Mokhtari; Atefeh Sadat Kamali; Bahareh Abtahi-Naeini; Mohammad Ali Nilforoushzadeh; Shayan Mostafaie
Journal:  Adv Biomed Res       Date:  2015-11-30

8.  Propranolol intervention therapy for infants with facial hemangioma.

Authors:  Jian Meng; Zhiping Li; Qianping Gu; Jie Zhang; Qianwei Zhuang; Yameng Si; Aixia Zhang
Journal:  Contemp Oncol (Pozn)       Date:  2012-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.